WHITEHAWK THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$3.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $32.00K.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$3.49M, a 458.36% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $4.67M, a 689.02% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $985.00K.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $3.92M.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$9.77M.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$132.00K, a 104.10% decline from fiscal 2022.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $3.22M, a 61.16% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.46M 10-Q · filed 2026-08-06 | $1.21M derived: sum of 3 quarters · filed 2026-08-06 | $2.19M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$3.49M 10-Q · filed 2026-05-07 | $1.18M derived: sum of 2 quarters · filed 2026-05-07 | $2.16M derived: sum of 3 quarters · filed 2026-05-07 | -$546.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $4.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.66M derived: sum of 2 quarters · filed 2026-03-12 | $2.95M derived: sum of 3 quarters · filed 2026-08-06 | $3.92M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $985.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.72M derived: sum of 2 quarters · filed 2026-08-06 | -$748.00K 10-Q · filed 2025-11-06 | -$156.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.73M 10-Q · filed 2026-08-06 | -$1.14M derived: sum of 3 quarters · filed 2026-08-06 | -$7.24M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $975.00K 10-Q · filed 2026-05-07 | $1.57M derived: sum of 2 quarters · filed 2026-05-07 | -$4.53M derived: sum of 3 quarters · filed 2026-05-07 | -$2.03M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $592.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$5.51M derived: sum of 2 quarters · filed 2026-03-12 | -$3.01M derived: sum of 3 quarters · filed 2026-03-12 | -$9.77M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | -$6.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.60M derived: sum of 2 quarters · filed 2025-11-06 | -$10.37M 10-Q · filed 2025-11-06 | -$5.55M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$4.27M 10-Q · filed 2025-08-07 | $549.00K derived: sum of 3 quarters · filed 2025-08-07 | $2.27M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | -$6.76M 10-Q · filed 2025-05-08 | -$1.95M derived: sum of 2 quarters · filed 2025-05-08 | -$226.00K derived: sum of 3 quarters · filed 2025-05-08 | -$5.35M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $6.54M derived: sum of 2 quarters · filed 2025-03-28 | $1.41M derived: sum of 3 quarters · filed 2025-03-28 | -$132.00K 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$3.40M derived: sum of 2 quarters · filed 2024-08-07 | -$4.95M 10-Q · filed 2023-11-08 | -$3.64M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-06-30 | -$5.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$6.67M 10-Q · filed 2024-08-07 | -$5.37M derived: sum of 3 quarters · filed 2024-08-07 | -$339.00K derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-03-31 | -$1.54M 10-Q · filed 2024-05-08 | -$241.00K derived: sum of 2 quarters · filed 2024-05-08 | $4.79M derived: sum of 3 quarters · filed 2024-05-08 | $5.80M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $6.33M derived: sum of 2 quarters · filed 2024-03-13 | $7.35M derived: sum of 3 quarters · filed 2024-03-13 | $3.22M 10-K · filed 2024-03-13 | |||
| 2022-09-30 | $5.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $6.05M derived: sum of 2 quarters · filed 2023-11-08 | $1.92M 10-Q · filed 2023-11-08 | $5.35M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$3.11M 10-Q · filed 2023-08-09 | $319.00K derived: sum of 3 quarters · filed 2023-08-09 | $3.96M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | -$4.13M 10-Q · filed 2023-05-10 | -$699.00K derived: sum of 2 quarters · filed 2023-05-10 | $2.94M derived: sum of 3 quarters · filed 2023-05-10 | $3.57M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $3.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $7.07M derived: sum of 2 quarters · filed 2023-03-29 | $7.70M derived: sum of 3 quarters · filed 2023-03-29 | $8.29M 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $3.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.27M derived: sum of 2 quarters · filed 2022-11-09 | $4.86M 10-Q · filed 2022-11-09 | $4.33M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $631.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.22M 10-Q · filed 2022-08-10 | $395.75K 10-Q · filed 2021-08-11 | $691.00K derived: sum of 3 quarters · filed 2022-08-10 | $2.54M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | $592.00K 10-Q · filed 2022-05-12 | $289.15K 10-Q · filed 2021-05-17 | $60.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.91M derived: sum of 3 quarters · filed 2022-05-12 | $2.35M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$532.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.32M derived: sum of 2 quarters · filed 2022-03-17 | $1.75M derived: sum of 3 quarters · filed 2022-03-17 | $1.08M 10-K · filed 2022-03-17 | -$1.44M 10-K · filed 2021-03-11 | ||
| 2020-09-30 | $1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.29M derived: sum of 2 quarters · filed 2021-11-10 | $1.61M 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $437.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$238.80K 10-Q · filed 2021-08-11 | |||||
| 2020-03-31 | -$675.86K 10-Q · filed 2021-05-17 | ||||||
| 2019-12-31 | -$2.22M 10-K · filed 2021-03-11 | ||||||
| 2018-12-31 | $1.86M 10-K · filed 2020-03-16 | ||||||
| 2017-12-31 | $1.60M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |